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Key messages: 
 
 
•This is the first systematic literature review on the use of ultrasonography in psoriasis and 
psoriatic arthritis; 
 
•The systematic literature review points up the importance and potential of ultrasonography in 
the management of psoriatic arthritis and psoriasis but it also underlines the need of a large 
amount of research to optimise the use of ultrasonography in the diagnosis and monitoring of 
psoriatic disease in clinical practice; 
 
•Based on the evidence arising from the literature review, a research agenda has been proposed. 
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Abstract 
Objective: To systematically review the role of musculoskeletal ultrasound (MSUS) in patients 
suffering from psoriatic arthritis (PsA) or psoriasis (Pso) in terms of prevalence, diagnosis, 
prognosis, monitoring and treatment.  
Methods: A systematic literature review was conducted through medical databases (MEDLINE via 
PubMed, Embase) and the grey literature up to September 2015 to inform a new study of the 
Musculoskeletal Ultrasound Study Group of the Italian Society for Rheumatology. All articles 
reporting data on MSUS in PsA or PsO were included and extracted according to the underlying 
clinical question.  
Results: 86 publications were included. The prevalence of US abnormalities showed a wide range 
for each examined feature (e.g. 37% to 95% for entheses thickness of the lower limbs). The 
performance of US for diagnosis of disease or elementary lesions was variable across studies but 
no study evaluated the overall performance of US in addition to clinical findings to diagnose PsA. 
Considering US in defining PsA and Pso prognosis, several works focused on US of entheses of 
lower limbs in Pso while for the monitoring of PsA activity, 5 different scoring systems were 
identified. Lastly, the results of the role of US to guide intra-articular interventions were 
controversial for the clinical outcomes while in favour of US for accuracy. 
Conclusion: despite the recognised importance of US in the management of PsA and Pso , this 
review  clearly demonstrated the need of a pivotal research to optimise the use of US in the 
diagnosis and monitoring of psoriatic disease. 
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Introduction 
Psoriatic arthritis (PsA) is a systemic inflammatory disease with articular and extra-articular 
features. In the last years, imaging is playing an increasing important role in the differential 
diagnosis and in monitoring treatment response in PsA. Recently, the European League Against 
Rheumatism (EULAR) recommendations for the use of imaging in the diagnosis and management 
of spondyloarthritis (SpA) advise the use of magnetic resonance imaging (MRI) and ultrasound (US) 
for the diagnosis, monitoring activity and evaluating structural changes in peripheral SpA (1). US 
demonstrated good accuracy, reliability and sensitivity to change in the assessment of various 
structures which may be involved in PsA, i.e. tendons, enthesis, synovium and bone (1–3). In 
addition, the information given by US assessment can be integrated to those obtained by clinical 
examination thus improving differential diagnosis (e.g. early seronegative polyarthritis), 
stratification of patients and therapeutic strategies in a treat-to-target (T2T) context (4,5). 
Currently, the utility of US in clinical practice is not yet supported by adequate evidence (6), 
therefore, reflecting the need to determine the role of US in diagnosis and prognostic stratification 
and to support prioritisation of US studies in PsA, the Musculoskeletal  Ultrasound Study Group of 
the Italian Society of Rheumatology decided to perform a systematic literature review (SLR) on the 
use of US in the management of PsA. 
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METHODS 
 
The Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) were followed 
to design and report this review(7). The most relevant areas of application of US in PsA and 
psoriasis (Pso) (prevalence and diagnosis of the disease, diagnosis of elementary lesions typical of 
PsA, prognosis, follow-up and treatment guide) were identified and pre-specified inclusion criteria 
for each item were developed (Table S1). 
Data Sources and Search 
PubMed and Embase were searched, without time limits, up to September 27th, 2015. The search 
strategy was developed based on search terms aiming at identifying studies including patients 
with PsA or Pso in which musculoskeletal US was performed. The search strategy is presented in 
Table S2. Abstract of the American College of Rheumatology (ACR) and EULAR congresses (2014 
and 2015) were hand searched. Studies had to be published in English, no publication restriction 
or selection based on quality were applied. 
Study Selection 
Studies included patients with suspected or confirmed PsA, including mixed population of arthritis, 
only when a part of patients diagnosed with PsA. Studies on patients with skin psoriasis without 
known arthropathy were also eligible for inclusion. US was considered as index test/intervention, 
details on the comparators, outcomes and eligible study designs are shown in Table 1. The 
reviewers (FB, AB, AZ) worked in pairs for each area of interest, independently screening titles and 
abstracts. The full-text of potentially eligible articles was obtained; inclusion assessment was 
performed by one reviewer and checked by a second.  
Data extraction and quality assessment 
Study characteristics and data were extracted using separate standardised forms for each area of 
interest. For diagnostic accuracy items, when possible data were extracted as 2x2 tables and 
sensitivity, specificity, positive and negative likelihood ratios (LR) with 95% confidence intervals 
(CI) were calculated. Pre-specified meta-analyses were not planned, due to the expected 
heterogeneity across studies. The hypothesis of heterogeneity was tested in the subgroup of 
studies assessing the performance of US in detecting elementary lesions. The risk of bias and 
methodological quality of the included studies were assessed with different tools, depending on 
study design. For diagnostic studies, the QUADAS-2 tool was used (8), for RCTs the risk of bias tool 
proposed by the Cochrane collaboration (9) while for observational studies the Newcastle-Ottawa 
scale (NOS) (10). 
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RESULTS 
Selected studies 
Of the 365 studies produced by PubMed and Embase search, 71 studies met the criteria for the 
inclusion. Furthermore 15 additional studies were included, 2 from hand search and 13 from the 
2014-2015 abstracts of ACR and EULAR. Figure 1 shows the flowchart of the study selection 
process. Table 2 highlights on high quality studies on prevalence, diagnosis and prognosis.  
Prevalence of US abnormalities in PsA and Pso 
The search retrieved 56 studies examining the prevalence of US abnormalities in PsA (50/56 
studies) and isolated Pso (6/50 studies) (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), 
(22), (23), (24), (25), (26), (27), (28), (29), (30), (31), (32), (33), (34), (35), (36), (37), (38), (39), (40), 
(41), (42), (43), (44), (45), (46), (47), (48), (49), (50), (51), (52), (53), (54), (55), (56), (57), (58), (59), 
(60), (61), (62), (63), (64), (65), (66). The results are summarized in Table 1, while complete results 
are shown in table S3. Regarding the examined US abnormalities, synovitis, erosions and 
enthesopathy were often studied, less frequently soft tissue inflammation, described as oedema 
and/or PD peri-tendinous. The prevalence of the examined lesions had a wide range in the studies: 
10 to 100% for synovitis (22), (34), (48), (52), (55); 37% to 94.5% for entheses thickness of the 
lower limbs (14), (17), (15), (24), (27), (30), (35), (36); and 10.8 to 52% for erosions (16), (34), (53), 
(55). The sites examined were very variable, except for studies of US entheses in which the lower 
limbs were the most frequently studied. For entheses evaluation Glasgow Ultrasound Enthesitis 
Scoring System (GUESS)  as the most commonly employed score (15), (17), (27), (41), (50), (59), 
followed by MASEI score (12), (26). Furthermore two studies evaluated the synovial contrast 
enhancement   with a prevalence in PsA of approximately 30 percent (33), (55).  The risk of bias for 
all selected studies, assessed using the NOS, is reported in table S3. 
 
Making a diagnosis of PsA 
Performance of US in the diagnosis of PsA and Pso 
The search retrieved 23 studies, including a qualitative systematic review (67), examining the 
performance of US to diagnose PsA (37), (40), (42), (45), (46), (47), (56), (58), (59), (12), (26), (27), 
(17), (20), (28), (19), (31),(30), (29), (21), (34)  ,(68). The results of the studies are summarized in 
Table S4,, figures 2, S1 and S2 . The diagnostic performance of US was variable across studies, in 
particular no study evaluated the overall performance of US in addition to clinical findings to 
diagnose PsA, while most studies were focusing on single lesions. However, no study 
demonstrated an adequate performance for US variables, considered separately. The performance 
of US to detect PsA was broadly variable among studies, with sensitivities ranging from 0.22 to 
1.00 for enthesopathy, from 0.16 to 0.76 for synovial hypertrophy and from 0.14 to 0.58 form joint 
bone erosions. Also sensitivities were extremely variables, ranging from 0.20 to 1.0 for 
enthesopathy, from 0 to 1.0 for synovial hypertrophy and from 0.40 to 1.0 for bone erosions. Most 
of the studies (22 out of 23) followed a cross-sectional case-control design, and the evaluation of 
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the diagnostic performance of US was in many cases not the primary objective of the study. As 
expected, the studies were heterogeneous in terms of examined sites and reference standard, 
although clinical diagnosis or classification criteria were the only standard adopted. The risk of 
bias, assessed by the modified version of the QUADAS, was in general considered high for the 
items concerning patients recruitment, unclear for the items dealing with the index test and 
mostly low for the items covering the reference standard and the timing (Figure S3). 
Performance of US in the diagnosis of PsA and Pso elementary lesions 
The search retrieved 30 studies examining the performance of US to diagnose PsA elementary 
lesions (11), (15), (16), (20), (23), (24), (25), (30), (32), (69), (33), (34), (37), (38), (39), (44), (45), 
(70), (47), (48), (51), (52), (71), (53), (55), (57), (58), (63), (64),(72). The results of the studies are 
summarized i in Table S5. The PsA elementary lesions evaluated were heterogeneous for type of 
lesions (e.g. synovial or extra-synovial features), anatomic structures and reference standard. The 
reference standard was clinical examination in 14 studies, MRI in 5, Conventional Radiography (CR) 
and arthroscopy in 3, Computer Tomography (CT) and Histological Evaluation (HE) in 1. 
Considering MRI as reference standard, the sensibility and specificity underwent wide variations 
depending on examined anatomic structures and types of lesions, for example considering 
synovitis, sensibility ranged from 0.49 to 0.94 while specificity from 0.20 to 0.91 (Figure S4). In the 
unique study using histopathology as reference, the amount of power Doppler did not significantly 
associate with a global histopathological inflammatory score (44); while for the single study 
comparing US with CT, a large proportion of bone lesions detected by US could be verified by CT 
(32). The risk of bias, assessed by the modified version of the QUADAS, was in general considered 
high for the items concerning patients’ recruitment, unclear for the items dealing with the 
reference standard and mostly low for the index test and flow and timing (Figure S5).  This 
subgroup of studies was used to test the presence of heterogeneity across studies (Supplementary 
Figure S6, available online only), showing a significant degree of heterogeneity (for joint 
abnormalities: Chi square= 785.46, p<0.0001 for the presence of heterogeneity; for entheseal 
abnormalities: Chi square=1027.29, p<0.0001 for the presence of heterogeneity). 
Prognosis and follow up 
Role of US in defining PsA and Pso prognosis 
The search retrieved 15 studies examining the role of US in defining PsA and Pso prognosis (11), 
(14), (73), (41), (74), (75), (56), (59), (23), (76), (77), (78),(79),(80), (49) with only two having a 
prospective design (75), (80). The results of the studies are summarized in Table S6. Several works, 
selected for this item, focused on target enthesis US in Pso patients revealing a high rate of 
subclinical inflammatory signs. Subclinical enthesitis, confirmed by a significant higher GUESS 
score, was found more frequently in Pso compared to healthy controls (14), (73), (41), while only 
one study focused on the prevalence of subclinical synovitis in Pso (49). There was only one 
prospective study, published by Tinazzi et al, in which GUESS scores of patients with Pso who 
developed PsA compared to those who did not develop PsA did not statistically differ. 
Furthermore, in the logistic regression analysis, baseline thickness of the quadriceps tendon was 
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found to be an independent predictor of the development of PsA (75). Moreover, the presence of 
PD signal in enthesis, evaluated as entheseal-organ in Aydin et al 2013 and within 2 mm of bone 
insertion in Gutierrez et al 2011, was  found to be highly specific for psoriatic disease (14), (41) . 
The risk of bias for all selected studies, assessed using the NOS, is reported in Table S6. 
Role of US in the follow-up of PsA and Pso  
The search retrieved 15 studies exploring the role of US in PsA follow up (81), (82), (18), (83), (69), 
(84), (85), (86), (87), (88), (89), (90), (91), (92), (63). The results are summarized in Table 3. In 
several studies, US assessment was used to analyze the response to a standardize therapeutic 
approach with inhomogeneous US endpoints. The comparison between articles is made difficult 
by the variability in definitions of elementary lesions and scoring systems, machine settings and 
image acquisition. Among selected articles, five different scoring systems have been tested. The 
US Group of Spanish Society of Rheumatology demonstrated that the PDUS examination of 14 
peripheral entheses was able to monitor the 6 months therapeutic response in 197 SpA patients  
(87). The German US7 scores, significantly reflected the therapeutic response of PsA patients 
evaluating synovitis, tenosynovitis and erosions of small joints whereas the SOLAR score, used to 
evaluate synovitis and tenosynovitis (GS and PD) of the large joints was able to monitor the 
treatment response in a cohort of PsA (82), (89). The “Five Targets Power Doppler for Psoriatic 
Disease” (5TPD) score was the first score including all domains characterizing PsA (joint, tendon 
with synovial sheath, enthesis, skin and nail) and those, one for each target area, showing the 
highest expression of PD were selected for monitoring an anti-TNF therapy for 8 weeks in 16 PsA 
patients (91). The 5TPD score showed a significant improvement during therapy but it did not 
correlate with HAQ-modified for SpA. Lastly, Ficjan et al. developed two US score (PsA-Son22 and 
PsA-Son13) in a prospective study on 83 consecutive PsA patients, these scores explored joints, 
peri-articular structures and entheses. Both composite scores had sufficient sensitivity to change 
and the bilateral score (PsA-Son22) was more sensitive than the unilateral score to detect PsA 
lesions whereas the unilateral (PsA-Son13)  was faster (90). The risk of bias, assessed using the 
“NOS, the “PRISMA Checklist” and the Cochrane diagnostic test Accuracy, was reported in Table 3. 
US to guide intra-articular interventions 
The search retrieved 4 studies, including two randomised controlled trials, examining the role of 
US to guide intra-articular interventions (93), (94), (95), (96). Among the twoRCT, comparing 
blinded and US-guided injections, the results were controversial for the clinical outcomes while 
the accuracy was better for US-guided procedures (95),(96). In Sibbit et al., US directed intra-
articular injections were superior to palpation-guided methods in all therapeutic measures: 
absolute VAS pain scores for injection pain were 81% less, responder rates were increased by 38%, 
and non-responder rates were reduced by 34% (96). Conversely, in the study published by 
Cunnington et al. there was no statistically significant difference between US-guided and blind 
injections for any of the major outcome variables (e.g. VAS pain, function and stiffness) measured 
at 2 weeks or 6 weeks (95). Only one study focused on tenosynovitis while no study focused on 
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enthesitis or bursitis (94). The risk of bias, assessed by the Cochrane Collaboration’s tool for 
intervention studies, is reported in figure S7. 
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DISCUSSION 
 
The usefulness of US in diagnosis, prognosis, and follow-up of inflammatory arthritis in clinical 
practice is still a matter of debate, despite the evidence of a higher sensitivity over clinical 
examination. Recently, an EULAR task force developed evidence-based recommendations on the 
use of imaging in the clinical management of RA and SpA (1) (97), acknowledging the need of 
further extensive research to optimise the use of imaging in routine clinical practice. On this basis, 
and in order to identify and prioritise its research agenda in the field of PsA, the Musculoskeletal  
Ultrasound Study Group of the Italian Society of Rheumatology, decided to plan a SLR with the aim 
to highlight the current state of knowledge. Currently, in early inflammatory arthritis, 
rheumatologists need supporting tools to strengthen the diagnosis (98). Among imaging 
modalities, US is the most attractive one, as less time consuming, safe and readily and easily used. 
For this reason, an increasing number of studies about US to diagnose PsA has been recently 
published. However, its use in clinical practice is still a matter of debate. In the SLR the diagnostic 
performance of US was widely variable and no study evaluated the overall performance of US in 
addition to clinical findings to diagnose PsA. Moreover, most of the selected diagnostic studies 
followed a cross-sectional case-control design, introducing a bias in patients selection and leading 
to an overestimation of the diagnostic performance of the index test. The ability of US to detect 
elementary lesions, which may support the diagnosis of PsA, is widely described in literature. 
Considering the potential pathogenetic role of enthesis in PsA, US of entheses was not surprisingly 
the most frequently used for diagnosis (42), (45), (46), (59), (81), (26), (27), (17), (31), (30), (11), 
(15), (23), (38), (39), (25), (24), (52). Furthermore, US was used to image synovitis, tenosynovitis, 
bursitis and erosions and less frequently soft tissue and hand nails. Clinical examination was often 
the reference standard for both the diagnosis of PsA and psoriatic elementary lesions. Only one 
study examined the performance of PD to identify synovitis using histopathology as gold standard, 
showing that a negative PD in the synovium did not exclude the possibility of synovitis (44). In 
axial, SpA imaging (conventional radiography and MRI of sacro-iliac joints) is a key component of 
classification criteria, mostly due to the absence of specific clinical symptoms (1), while in the 
classification of peripheral inflammatory arthritis, its use is not mandatory. However, in early 
disease imaging might play an important role supporting diagnosis and directing the treatment. 
Regarding the differential diagnosis, studies seem to support the idea that PsA could be 
differentiated from RA for a major extra-synovial involvement. Soft tissue inflammation, described 
as oedema and/or PD peri-tendinous, could be a very distinctive sign of PsA, being absent in RA 
controls (45), (34), (40). Fourniè et al. highlighted a major synovial involvement in RA than PsA (i.e. 
100% vs 76%) and furthermore, the prevalence of erosions was lower in PsA than in RA (34), (58), 
(60), (63), even though this result was recently questioned by another study (45). Moreover, the 
prevalence of features differed greatly between selected studies, mainly due to the heterogeneity 
of inclusion criteria, elementary lesion definitions and equipment. In addition, possible sources of 
bias mainly related to patient selection might have been present. With clinical remission being the 
ideal treatment target, the application of US to predict development of arthritis in Pso patients or 
to identify PsA patients with poorer outcome, is of interest. Considering the importance of 
enthesitis as the key lesion in PsA, some studies focused on entheses of lower limbs in psoriatic 
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disease (with or without arthritis) revealing an high rate of enthesopathy signs (73), (14), (41), 
particularly for PD activity. The results of SLR supported the idea that entheseal PD, rather than GS 
changes, is a highly specific feature for PsA. However, the prognostic role of these lesions in the 
development of arthritis in Pso patients is not clear yet. There was only one prospective work by 
Tinazzi et al. demonstrating that in Pso patients, baseline thickness of quadriceps tendons was an 
independent predictor of PsA development, and suggesting the need of further investigation in 
larger cohorts in order to understand the real predictive value of the entheses US (75). Currently, 
in RA synovitis, tenosynovitis and bone marrow oedema appear to be predictors of radiographic 
progression and synonymous of disease activity (99), (100), (101), (94). To date, in PsA, US 
predictors of poorer outcome have not been identified, moreover many studies had an 
unappropriated design to evaluate prognostic measures. Since in RA T2T studies based solely on 
US did not prove a superiority of imaging over clinical management (102), the potential role of US 
in monitoring disease activity has to be tested in addition to clinical follow-up. The integration of 
US with clinical examination to stratify patients and to decide treatments in a T2T strategy also 
represents an interesting possibility. The SLR identified few US scores to monitor disease activity in 
PsA patients. German US7 scores, developed in RA, was the first applied and was able to 
significantly reflect the therapeutic response of PsA patients evaluating synovitis, tenosynovitis 
and erosions (82). Focusing on large joints, the SOLAR score, was used to evaluate activity in a 
cohort of PsA and Ankylosing Spondylitis patients and the authors concluded that it was a valuable 
tool (89). Furthermore, the Group of Spanish Society of Rheumatology demonstrated that the 
PDUS examination of 14 peripheral entheses was able to monitor the response of SpA patients 
during anti-TNF therapy, and interestingly the authors highlighted that the score may contribute 
to the development of a cumulative scoring system of combined elementary lesions (87). 
Considering the clinical heterogeneity of PsA with different domains and peculiar sites involved, a 
dedicated ultrasound composite score is arguably necessary. First, Gutierrez et al. developed a PsA 
dedicated preliminary five target score for the assessment of PsA patients during anti-TNF therapy 
(91). Later, also Ficjan et al. proposed two PsA specific US score (PsASon-13 and PsASon-22) to 
monitor disease activity in PsA (90). All these last three scores are original and interesting, but 
they are not applied in other series, thus remaining preliminary scores despite good sensitivity for 
the detection of inflammation and feasibility. Despite the extensive use in clinical practice, 
superiority for clinical outcome of US-guided injections over blinded injections remains doubtful in 
PsA and further studies are needed to better define the efficacy of one over the other. US-guided 
injections resulted to be overall more accurate. Accordingly Cunnington et al. recommended US-
guided procedures in joints that were frequently injected inaccurately (e.g. shoulder, ankle, hip) 
and in order to reduce tissue necrosis or the possible damage to surround tissues (98). Therefore 
actually, safety data seem to be an added value of US-guided injections. Although the SLR pointed 
up the importance and potential of US in the management of PsA and Pso, it also underlined the 
need of a large amount of research to optimise the use of US in the diagnosis and monitoring of  
psoriatic disease in clinical practice. In particular, several gaps in the literature were underlined, as 
well as the presence of possible biases, such as patient selection and reference standard for 
diagnostic studies or to randomisation in interventional studies. In addition, since the presence of 
publication bias was not investigated, it cannot be excluded. Based on the evidence arising from 
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the literature review, a research agenda has also been proposed (Table 4). Considering the gaps of 
the literature underlined by the SLR, the Ultrasound Study Group of the Italian Society for 
Rheumatology gave priority to a novel study aiming to identify clinical and US predictors of 
Minimal Disease Activity in PsA patients with active peripheral arthritis starting a new course of 
therapy (Ultrasound in Psoriatic Arthritis Treatment – UPSTREAM study). Identifying prognostic 
factors of achieved remission or low disease activity will help a better selection of patients with 
poorer outcome and possibly the improvement of therapeutic strategies, responding to the need 
of personalized medicine, optimizing the outcome of patients with PsA as well as the treatments 
management. 
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TABLES 
 
Table 1: prevalence of US abnormalities (range, %) across primary studies 
PsA patients Prevalence on site examined (%) Prevalence on patient (%) 
Gray Scale Synovitis 14.0 – 57.0 10.0-100.0 
Power Doppler Synovitis 2.0 – 8.7 28.6 – 73.0 
Joint erosions 6.1 – 57.7 10.8 – 52.0 
Increased thickness of lower 
Limbs entheses: 
10.0 – 43.1 37.0 - 94.5 
PD at enthesis 0.0 - 7.4 15.6 - 40.2 
Entheseal erosions 5.0 – 14.9 0.0 – 10.8 
Soft tissue inflammation  38.9 – 65.8 14.3 – 32.0 
 
 
 
 
Table 2. Summary table on prevalence, diagnosis and prognosis reporting high quality studies (i.e. relevant 
results for the reviewers and including at least 20 PsA patients or 30 Pso patients). that included at least 20 
PsA patients or 30 Pso patients . Full results are reported in the supplementary online material. 
 
Study N Population Control Examined structures Equipment Area of interest 
Aydin et al. 2012  42 PsA Cutaneous psoriasis 
with nail disease 
20 HC Nail  GE Logiq E9, 10-
18 Mhz 
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions 
Aydin et al. 2013 58 PsA Cutaneous psoriasis 
including PsA 
42 Pso; 23 HC Lower limb entheses GE Logiq E9 and 
Logiq5 machine 
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions; 
Prognosis 
Bandinelli et al. 
2015 
112 PsA PsA with symptoms 
onset < 1 year 
- MCP-PIP-DIP joints; 
flexor and extensor 
digitorum tendons; 
radio and intercarpal 
joints 
Esaote MyLab70 
XVG, 6-18 Mhz 
Disease prevalence; 
Diagnosis of elementary 
lesions 
Eder et al. 2014 50 PsA PsA 66 Pso; 60 HC Enthesis included in 
the MASEI score 
Esaote MyLab 
70XVG, 6–18 MHz  
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions 
Fourniè et al. 2006 20 PsA PsA and RA 21 RA Hand joints (MCP, PIP 
and DIP); Extensor and 
flexor tendon; Soft 
tissue 
Siemens Sonoline 
Elegra, 13.5 Mhz 
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions 
Freeston et al. 
2012 
42 PsA Early PsA (<24 
months) 
10 HC Lateral epicondyles of 
the elbow, inferior 
patellar tendon 
insertion, Achilles 
tendon, plantar fascia 
Philips HDI 5000, 
5-12 and 7-15 
MHz  
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions 
Freeston et al. 
2014 
49 PsA Early PsA (<24 
months) 
8 HC Bilateral posterior 
glenohumeral joints, 
olecranon fossa, 
Philips HDI 5000 
machine, 5-12 
MHz and 7-15 
Disease prevalence; 
Diagnosis of elementary 
lesions 
Ultrasonography in Psoriatic Arthritis 
22 
wrists, MCP and PIP 
joints, knees, 
tibiotalar and MTP 
joints 
 
MHz 
Gisondi et al. 2008 30 Pso Pso without any 
clinical evidence of 
arthritis or enthesitis 
30 HC Target enthesis 
(GUESS score) 
ATL HDI 3000, 10–
15 MHz probe 
Prognosis 
Gutierrez et al. 
2011 
20 PsA PsA and RA 18 RA MCP joints Esaote MyLab70 
XVG 6-18 Mhz 
Disease prevalence; 
Diagnosis of PsA and 
elementary lesions 
Gutierrez et al. 
2011 
45 Pso Pso without any 
clinical evidence of 
arthritis or enthesitis 
45 HC Target enthesis of 
GUESS score 
Esaote MyLab70 
XVG 6-18 Mhz 
Disease prevalence; 
Prognosis 
Husic et al. 2014 70 PsA PsA - 68 joints and 14 
entheses 
Esaote 
MyLabTwice, 6-18 
Mhz 
Prognosis 
Marchesoni et al. 
2012 
30 PsA PsA and Fibromyalgia 
(FM) 
30 FM 14 target enthesis GE Logiq5, 8-15 
Mhz 
Disease prevalence; 
Diagnosis of PsA 
Naredo et al. 2011 162 Pso Plaque psoriasis 60 controls 
with other 
skin disease 
wrist, MCP- PIP 
and DIP joints of the 
hands, knee, tibiotalar 
joint; extensor tendon 
of the wrist; finger 
flexor tendon; target 
enthesis 
GE Logiq 9, 8-14 
Mhz 
Disease prevalence; 
Prognosis 
Tinazzi et al. 2011 30 Pso Pso - Target enthesis 
(GUESS score) 
ATL HDI 3000, 10–
15 MHz probe; 
GE Logiq5, 10-15 
Mhz 
Prognosis 
Zayat et al. 2015 60 PsA PsA, RA, gout and OA 70 RA, 60 
gout, 60 OA, 
60 HC 
distal articular radius 
and ulna, II-III and V 
MCP joints, II-III PIP 
joints and I and V MTP 
joints, 2nd, 3rd 
 
GE LogiqE9, 6-15 
Mhz 
Disease prevalence; 
Diagnosis of elementary 
lesions 
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Table 3: Studies evaluating  US in monitoring PsA. US: ultrasonography.   
Study N Study design Inclusion criteria Examined structures Equipment  Results Risk of bias 
Acquacalda 
2015 
22 Pso 
12 PsA 
Prospective cohort CASPAR before introduction of the first 
systemic treatment or biologic 
5 entheses 
Hypoechogenicity, 
thickness, erosion, calcification, PD, 
morphological/structural lesion 
Esaote 
MyLab70 XVG 
US morphological abnormalities (baseline vs 6 months) 
PsO 30% vs 17.7% P=0.021 
PsA (PD) 33% vs 24% p=0.164 
Sel **  
Comp **  
Exp ** 
Backhaus 
2009 
120 
patients  
(PsA 9%) 
Prospective cohort PSA starting new therapy Wrist, 2nd- 3rd MCP and PIP, 2nd-5th  
MTP 
GS and PD 
Different US 
machines 
3 months:  
synovitis GSUS/DAS28 r=0.44, p<0.05 
PDUS/DAS28 r=0.44, p<0.05 
tenosynovitis GSUS/DAS28 r=0.11, p>0.05 
  PDUS/DAS28 r=0.11, p>0.05 
Erosions/DAS28 r=0.11, p>0.05 
6 months: 
synovitis GSUS/DAS28 r=0.38, p<0.05 
PDUS/DAS28 r=0.31, p<0.05 
tenosynovitis GSUS/DAS28 r=0.26, p<0.05 
  PDUS/DAS28 r=0.24, p<0.05 
Erosions/DAS28 r=0.16, p>0.05 
Sel ***   
Comp   
Exp * 
Bonifati 
2014 
25 PsA Retrospective 
cohort 
CASPAR criteria, ETA o ADA (>12 months) Target joints 
US contrast-enhanced 
- Positive CEUS  (baseline vs 12 months) 
22/25 vs 3/25 p<0.0001 
Sel ***   
Comp   
Exp ** 
Cozzi 2015 36 PsA RCT CASPAR, TNFi >6 months All joints of both hands Esaote My Lab CEUS in PsA receiving mud-bath (baseline-45 days): High Risk 
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US contrast enhanced 70 seconds, mean (sd) 
Time of appearance  22.21 (8.79) vs 25.71 (12.81) p<0.05 
Washout rate 9.32 (0.49) vs 9.12 (0.78) p>0.05 
Peak value 0.14 (0.06) vs  0.13 (0.04) p>0.05 
Contrast flow  0.07 (0.03) vs 0.06(0.03) P<0.05 
Ficjan 2014 83 PsA Prospective cohort CASPAR, peripheral articular manifestations PsASon 22, bilateral score included 
22 joints and 4 entheses. 
 
PsASon13, unilateral score included 
13 joints and 2 entheses 
Esaote My Lab 
Twice 
PsASon 22 and 13 (6 months) 
Global ultrasound inflammation subscore: 
SRM:  −0.53 to −0.04 (entire cohort) 
−1.04 to −0.09 (pts from active disease to MDA) 
ICC:  0.84 (PsASon22),  0.54 (PsASon 0.96) 
Sel ***   
Comp   
Exp *** 
Fiocco 1996 
 
23 
patients 
(11 PsA) 
Prospective cohort Moll and Wright, Knee joint pain, patients 
treated with NSAIDs and second-line drugs >6 
months 
Knee 
Joint effusion/Synovial Tickness 
7.5 MHz 
electronic linear 
transducer/10 
MHz 
mechanical 
sectorial 
transducer 
Significant correlation between clinical and US indexes at 
all timepoints (baseline, 2 months, 6 months, 12 months) 
Sel **  
Comp *  
Exp ** 
Fiocco 2005 27 
patients 
(8 PsA) 
Prospective cohort Moll and Wright Criteria, eligible for TNFi Involved knee 
Synovitis  
PD 
Elegra, Siemens F/SI-PD mean (sd) 
Baseline 1.31 (0.30) ; 3 months 0.63 (0.21) p<0.001;  12 
months 0.44 (0.20) p<0.05 
P/CI-PD mean (sd) 
Baseline 1.59 (0.21), 3 months 1.62 (0.018) p>0.05; 12 
months 0.89 (0.18) <0.05 
Sel ***   
Comp   
Exp ** 
Fraser 2005 72 PsA RCT 18-70 years, PsA criteria 1994 >24 weeks, 2nd-5th MCP and PIP of the ATL HDI 3000 US synovitis reduction after 12 months Unclear 
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active PsA and Pso, no response to MTX dominant hand -2.5 (95% CI -4.07, -1.01) 
Keen 2011 
 
 
- Systematic review published studies in English, humans, 
comparing imaging of structural tissue 
Involved knee 
Synovial thickness, effusion size, PD 
- US internal responsiveness was found with regard to 
synovial thickness, effusion size, and popliteal cyst size. 
External responsiveness was demonstrated against several 
referenced health status measures. 
No quantitative synthesis, references were screened. 
PRISMA Checklist: 
20/28 
Gutierrez 
2012 
16 PsA Prospective cohort CASPAR, starting therapy with ADA, ETA, IFX MCPs, MTPs, wrists, 
finger flexor tendons,  tibialis 
posterior  tendons, peroneous 
tendons, entheses (Achilles tendon, 
distal and  proximal insertion of 
patellar tendon), psoriatic plaques, 
nails. 
Esaote My Lab 
70 XVG 
Median (IQR) 5 target PD: 
Baseline 9 (4-12),   8 weeks 3 (1-5), p=0.0001 
Inter-reader realiability baseline k:  joint 0.74, tendon 0.79  
enthesis 0.97, nail 0.65, skin 0.88 
Intra-reader  reliability  baseline k:  joint 0.98, 
tendon  0.98, enthesis  0.97, nail = 0.82, skin 0.94 
Sel ***  
Comp   
Exp ** 
Naredo 
2010 
327 SpA Prospective cohort ESSG or Amor criteria, starting  TNF i 14 peripheral entheses. 
Morphologic abnormalities, Calcific 
deposits, Cortical abnormalities, 
adjacent bursitis, PD 
Logiq 5 PRO; 
(General 
Electric) 
Baseline vs 6 months (mean , sd) 
Morphologic abnormality score 2.19 (2.66) vs  1.34 (2.02) 
p<0.0005 
Calcific deposit score 1.11 (1.63) vs 1.23 (1.79) p =0.142 
Cortical abnormality score 3.92 (3.73) vs  4.17 (3.86) 
p=0.036 
Adjacent bursitis score 0.94 (1.21) vs  0.76  (1.19) p=0.036 
Intraenthesis PD  1.36 (2.11) vs 0.68 (1.64) p<0.0005 
Perienthesis PD  1.75 (2.92) vs  0.98 (2.23) p<0.0005  
Sel ***   
Comp   
Exp *** 
Teoli 2012 40 PsA Retrospective 
cohort 
CASPAR; therapy with ADA Most clinically involved joints. 
Synovial effusion, synovial 
Logiq 5 Pro 
(General 
Baseline vs 24 months score (mean , IQR) 
Synovial effusion 2.3 (1–3) vs 0.1 (0-1) 
Sel ***   
Comp   
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proliferation, PD Electric) Synovial proliferation  1,125 (0–2) vs 0,025 (0-1) 
PD  2.5 (1–3) vs  1 (0–2) 
Bone erosions 0,2 (0–2) vs  0,25 (0–2) 
Exp ** 
Schafer 
2013 
126 SpA Prospective cohort CASPAR Shoulder, elbow, hip, knee 
Solar score (GS/PD) 
- Baseline vs 6 months score (mean, sd) 
Shoulder GS  2.8  (1.9) vs 1.1 ( 1.2) p<0.05 
                 PD 1.7  (1.6) vs 0.4 (0.8) p<0.05 
Elbow GS 4,3 (2.6) vs 0.9 (1.5) p<0.05 
            PD 2.3 (2.0) vs 0.6 (1.1) p<0.05 
Hip GS  2.0 (0.8) vs 1.0 (1.1) p<0.05 
       PD 0.7 (0.9) vs 0.3 (0.5) p>0.05 
Knee GS 5.3 (2.9) vs 2.8 (2.8) p<0.001 
          PD 2.9 (3.1) vs 1.4 (2.4) p<0.05 
Sel ***   
Comp   
Exp *** 
Coates 2015 89 PsA Retrospective 
cohort 
Early PsA Hands US 
Erosions 
Unclear Erosions (%) baseline vs 48 weeks  
3.5% vs 5.6% 
Unclear 
PsA: psoriatic arthritis; Pso: psoriasis; HC;  N: number; GS: grey-scale, PD: power Doppler; MCP: metacarpophalangeal joints; PIP: proximal interphalangeal joints; MTP: metatarsophalangeal joints; CASPAR: Classification criteria for psoriatic 
arthritis, PASI: psoriasis area severity index; TNFi: tumor necrosis factor inhibitors; ADA: adalimumab; ETA: etanercept; IFX: inflizimab; MTX: methotrexate; CSA: cyclosporine A; NSAIDs: non steroideal anti-inflammatory drugs; F/SI-PD: 
fluid/synovium interface; P/CI-PD pannus/cartilage or pannus/ capsule interface. 
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Table 4: Research Agenda of US in PsA and Pso patients 
 
1. To investigate the integration of US in clinical practice in order to improve the certainty of diagnosis 
2. To investigate which US elementary lesions could be highly specific for PsA 
3. To investigate the prognostic role of US in identifying Pso patient at risk to develop PsA 
4. To further analyse US score in order to monitor disease activity 
5. To identify US predictors of treatment response in order to stratify treatment regimen (i.e. better selection of 
patients with poorer outcome) 
6. To further analyse the supposed superiority of US guided injection compared to palpation guided injection 
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FIGURES 
 
Figure 1:  flow-chart showing the selection process. 
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Figure 2: Performance of US variables to diagnose PsA: sensitivities and specificities of primary studies. A: 
synovial abnormalities/joint effusion; B: entheseal abnormalities; C: tendon abnormalities; D: bone 
erosions. No US abnormality, considered alone, had an optimal diagnostic performance to diagnose PsA. 
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